Celea Therapeutics to Present Phase 3 Trial Data for IPF Treatment at ERS Congress
Event summary
- Celea Therapeutics will present two key studies on deupirfenidone (LYT-100) at the ERS Congress in Barcelona from September 5-9, 2026.
- SURPASS-IPF is the first industry-sponsored Phase 3 head-to-head trial comparing deupirfenidone to pirfenidone in idiopathic pulmonary fibrosis (IPF).
- Phase 1 drug-drug interaction study shows no significant interactions between deupirfenidone and nintedanib.
- Deupirfenidone has Orphan Drug Designation from the FDA and European Commission.
The big picture
Celea Therapeutics' presentations at the ERS Congress highlight the advancing clinical profile of deupirfenidone, a next-generation antifibrotic therapy for IPF. The Phase 3 trial design and drug interaction data are critical for establishing its potential as a new standard of care. The IPF market has seen limited treatment options with modest efficacy, making deupirfenidone's development a strategic opportunity to address unmet medical needs.
What we're watching
- Trial Outcomes
- Whether the SURPASS-IPF trial results will demonstrate superiority of deupirfenidone over existing IPF treatments.
- Regulatory Pathway
- The pace at which deupirfenidone could secure full approval if Phase 3 trials are successful.
- Market Positioning
- How Celea Therapeutics positions deupirfenidone against competitors in the IPF treatment landscape.